Full Text View
Tabular View
Study Results
Related Studies
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
This study has been completed.
Study NCT00345579   Information provided by GlaxoSmithKline

First Received on June 26, 2006.   Last Updated on February 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Haemophilus Influenza Infections
Additional conditions recognized in this trial
Haemophilus Infections
Influenza, Human
More general conditions related to this trial
Bacterial Infections
Gram-Negative Bacterial Infections
Orthomyxoviridae Infections
Pasteurellaceae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
ActHIB
Pediarix/Infanrix Penta
Additional drug interventions recognized in this trial
PENTA
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services